Real-world data on the effectiveness of risankizumab as induction therapy for ustekinumab-refractory ulcerative colitis
Open Access
- 10 August 2026
- journal article
- Published by Korean Association for the Study of Intestinal Diseases in Intestinal Research
Abstract
Real-world data on the effectiveness of risankizumab as induction therapy for ustekinumab-refractory ulcerative colitisKeywords
This publication has 4 references indexed in Scilit:
- Comparative Efficacy of Biologics and Small Molecule in Ulcerative Colitis: A Systematic Review and Network Meta-analysisClinical Gastroenterology and Hepatology, 2024
- Risankizumab as maintenance therapy for moderately to severely active Crohn's disease: results from the multicentre, randomised, double-blind, placebo-controlled, withdrawal phase 3 FORTIFY maintenance trialThe Lancet, 2022
- Risankizumab as induction therapy for Crohn's disease: results from the phase 3 ADVANCE and MOTIVATE induction trialsThe Lancet, 2022
- Patient With Ulcerative Colitis and Failure of Ustekinumab Responds to Risankizumab: Similar Is Not IdenticalInflammatory Bowel Diseases, 2022